Stockscreener 앱 받기
102.38
1.13%
1.14
Incyte Corp 주식(INCY)의 최신 뉴스
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability - ChartMill
Incyte’s sale of Wilmington offices generates just 10 cents in real estate taxes - Spotlight Delaware
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
INCY insider files Form 144 to sell 2,639 shares (INCY) - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Zilurgisertib FOP data to debut at ENDO 2026 before Sept. 26 FDA PDUFA date - Stock Titan
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative
Incyte (NASDAQ: INCY) exec has 25,469 shares withheld to cover taxes - Stock Titan
Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus - Bez Kabli
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Citizens maintains Incyte stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Stifel reiterates Incyte stock Buy rating on DLBCL data strength - Investing.com
H.C. Wainwright reiterates Incyte stock rating on lymphoma data - Investing.com
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL - BioSpace
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasit - GuruFocus
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasitamab - GuruFocus
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma - GuruFocus
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters - Investing.com
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% - Stock Titan
Incyte (INCY) accounting officer sells 2,051 common shares - Stock Titan
INCYTE (NASDAQ: INCY) director exercises 15,000 options and has shares withheld for taxes - Stock Titan
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Morgan Stanley sells INCY common shares (INCY) via Form 144 notice - Stock Titan
DIADEMA PARTNERS LP's Incyte Corp(INCY) Holding History - GuruFocus
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte to stream Goldman Sachs healthcare conference talk June 9 - Stock Titan
1INCY.MI Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (BIT:1INCY) - ChartMill
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - Barchart.com
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup - ChartMill
Continuum Advisory, LLC's Incyte Corp(INCY) Holding History - GuruFocus
INCY Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
3.22%
1.54%
자본화:
|
볼륨(24시간):